Results 1 to 10 of about 96,125 (258)
Journal of the American Heart Association, 2021 Background It remains unclear whether beta‐blocker use at hospital admission is associated with better in‐hospital outcomes in patients with acute decompensated heart failure.
Moritake Iguchi, Yusuke Yoshikawa
exaly +3 more sources
J Educ Teach Emerg MedThis simulation is intended to be used for emergency medicine (EM) residents (all levels) and 4th year medical students.Beta-blocker (BB) toxicity ranks seventh among the top 25 substances associated with fatalities, with a cardiovascular mortality rate of up to 1.4%.1,2 Patients with BB overdose may present with bradydysrhythmias, hypotension ...
Vempati A, Greene PJ.
europepmc +4 more sources
The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants [PDF]
Clinical and Translational SciencePrevious pharmacogenetic findings for beta‐blocker pharmacodynamic candidate genes (ADRB1, ADRB2, ADRA2C, GRK4, and GRK5) have been inconsistent. Therefore, the purpose of this study was to determine whether interactions of pharmacodynamic variants with ...
Jasmine A. Luzum +5 more
doaj +2 more sources
Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia [PDF]
Annals of HematologyAllogeneic hematopoietic stem cell transplantation (HSCT) is curative for patients with acute myeloid leukemia (AML) through an immune-mediated graft-versus-leukemia effect, but relapse is common. Studies in solid tumors have shown that adrenergic stress
Johanna Werk +9 more
doaj +2 more sources
Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib [PDF]
MedicinaBackground and Objectives: Erlotinib, a tyrosine kinase inhibitor (TKI), is an established therapy for patients with metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.
Oğuzhan Yıldız +9 more
doaj +2 more sources
Medicina, 2023 Background and Objectives: Osteoporosis results in increasing morbidity and mortality in hemodialysis patients. The medication for treatment has been limited.
Suthiya Anumas +4 more
doaj +1 more source
A Clinical-Epidemiological Study on Beta-Blocker Poisonings Based on the Type of Drug Overdose
Journal of Toxicology, 2023 Background. Beta‐blockers carry a high risk of potentially causing fatal poisoning if overdosed. We aimed to assess the clinical and epidemiological characteristics of patients with beta-blocker poisoning. Methods.
Nastaran Eizadi-Mood +4 more
doaj +1 more source
Beta-blockers for hypertension [PDF]
Cochrane Database of Systematic Reviews, 2017 Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line
Wiysonge, Charles S. +4 more
openaire +3 more sources
Swiss Medical Weekly, 2020 BACKGROUND The European Society of Cardiology recommends beta-blocker prescription after ST-segment elevation myocardial infarction (STEMI).
Christel Bruggmann +5 more
doaj +1 more source
ESC Heart Failure, 2021 Aims The number of patients with both chronic obstructive pulmonary disease (COPD) and heart failure (HF) is increasing in Asia, and these conditions often coexist.
Yoshiaki Kubota +13 more
doaj +1 more source